Health

A large retrospective cohort study has found that different molecular subtypes of breast cancer have varying rates and patterns of recurrence following surgery for early-stage disease. The study analyzed the data of 16,462 women who had undergone surgery for breast cancer at the Seoul National University College of Medicine from 2000 to 2018. The study
The optimal induction systemic regimen for patients with initially unresectable colorectal cancer liver metastases is yet to be established. Published data in this patient population are difficult to interpret due to absent or varying criteria for resectability or unresectability, scarcity of long-term follow-up of patients who received local treatment, and heterogeneity in study populations, trial
Researchers have found that Letermovir, sold under the brand name Prevymis, is just as effective as the standard prophylaxis, Valganciclovir, in preventing cytomegalovirus (CMV) disease in high-risk kidney transplant patients. CMV disease is a major cause of morbidity and mortality in kidney transplant recipients, especially in those who receive an organ from a CMV-seropositive donor.
A randomized trial conducted to test the efficacy of perioperative pembrolizumab in operable non-small cell lung cancer (NSCLC) has shown positive results. The trial showed a 42% reduction in risk for disease recurrence or death, thereby supporting the use of PD-1 checkpoint inhibitor in stage II-III NSCLC. Although the trial did not show a significant
A phase III trial conducted by SWOG S1826 has revealed that the immune checkpoint inhibitor nivolumab (Opdivo) is more effective than brentuximab vedotin (Adcetris) in reducing disease progression or death in newly diagnosed adults and adolescents with advanced-stage classical Hodgkin lymphoma (cHL). Research Findings The trial involved over 976 patients with newly diagnosed stage III-IV
In mid-stage trials, two newer targeted therapies have shown meaningful activity against HER2-positive biliary tract cancers in pretreated patients with advanced disease. According to Shubham Pant, MD, of the MD Anderson Cancer Center in Houston, cohort 1 of the global HERIZON-BTC-01 study, which included 80 treatment-refractory patients, showed that 41.3% responded to zanidatamab, an investigational
A small case-control study has revealed that an index of gliosis was associated with persistent neurocognitive symptoms after mild or moderate SARS-CoV-2 infection. Researchers found that PET measures of translocator protein total distribution volume (TSPO VT), a marker of gliosis, were elevated in people with ongoing cognitive and depressive symptoms after COVID-19. In comparison to